ScholarIQanswers from OpenAlex & ORCID
Jingqin Luo
ResearcherPublications, citations & collaboration network
Jingqin Luo is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jingqin Luo have?
ScholarIQindexed works
Jingqin Luo has 714 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jingqin Luo have?
ScholarIQcitation count
Jingqin Luo has 16,700 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jingqin Luo?
ScholarIQh-index
Jingqin Luo has an h-index of 57 in OpenAlex.
What is the i10-index of Jingqin Luo?
ScholarIQi10-index
Jingqin Luo has an i10-index of 149 in OpenAlex.
What is the ORCID of Jingqin Luo?
ScholarIQorcid
The ORCID for Jingqin Luo is on the source record.
What is the OpenAlex record for Jingqin Luo?
ScholarIQopenalex
The OpenAlex for Jingqin Luo is on the source record.
What are the most-cited papers on Jingqin Luo?
ScholarIQmost cited works
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis, Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian Andrew Van Tine, Jeremy Hoog, Reece Goiffon, Theodore C. Goldstein, Sam Ng, Lin Li, Robert J. Crowder, Jacqueline Snider, Karla V. Ballman, Jason D. Weber, Ken Chen, Daniel C. Koboldt, Cyriac Kandoth, William Schierding, Joshua F. McMichael, Christopher A. Miller, Charles Lu, Christopher Harris, Michael D. McLellan, Michael C. Wendl, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie A. Margenthaler, Gildy V. Babiera, P. Kelly Marcom, J. Michael Guenther, Marilyn Leitch, Kelly K. Hunt, John A. Olson, Tao Yu, Christopher A. Maher, Lucinda Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L. Vickery, Adnan Elhammali, Helen Piwnica‐Worms, Sandra McDonald, Mark A. Watson, David J. Dooling, David M. Ota, Li-Wei Chang, Ron Bose, Timothy J. Ley, David Piwnica‐Worms, Joshua M. Stuart, Richard K. Wilson, Elaine R. Mardis
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Lin Li, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly K. Hunt, John A. Olson